Mastocytosis

Mastocytosis — scientific infographic poster

Mastocytosis is a clonal mast cell disorder caused by an activating mutation in the KIT gene (most commonly KIT D816V), which encodes the stem cell factor receptor CD117. This mutation drives ligand-independent signaling, resulting in uncontrolled mast cell proliferation and accumulation in one or more organ systems. The condition spans a wide spectrum from skin-limited disease in children to aggressive systemic forms in adults requiring targeted kinase inhibitor therapy.

🤧 Interactive Visualization Histamine, Mast Cells & Allergy — trigger a mast cell yourself Arm a mast cell with immunoglobulin E (IgE), let the allergen cross-link it, and watch histamine burst out to raise a wheal — then block the H1 receptor and see symptoms fall while histamine still pours out. Launch →

Table of Contents

  1. Overview and Classification
  2. Cutaneous Mastocytosis
  3. Systemic Mastocytosis — Subtypes and WHO Criteria
  4. Clinical Manifestations — Mediator Symptoms
  5. Bone Manifestations and Osteoporosis
  6. Diagnosis — Laboratory and Pathology
  7. Treatment — Symptomatic Management
  8. Treatment — Advanced Systemic Mastocytosis
  9. Hereditary Alpha-Tryptasemia
  10. Key Research Papers
  11. Connections
  12. Featured Videos

Overview and Classification

Mastocytosis arises from a clonal expansion of mast cells carrying an activating mutation, most commonly KIT D816V — a single amino acid substitution (aspartate to valine at position 816) in the activation loop of the KIT tyrosine kinase receptor. This substitution renders the receptor constitutively active without requiring stem cell factor (SCF) ligand binding, driving autonomous mast cell proliferation.

The KIT gene encodes CD117, the stem cell factor receptor expressed on mast cells, hematopoietic progenitors, and melanocytes. In normal physiology, SCF binding induces receptor dimerization and downstream signaling through RAS/MAPK and PI3K/AKT pathways. The D816V mutation bypasses this requirement. This mutation is found in over 90% of adult systemic mastocytosis cases and in a significant proportion of pediatric cases.

The two major categories of mastocytosis are:

Back to Table of Contents

Cutaneous Mastocytosis

Cutaneous mastocytosis is the most common form of mastocytosis in children and is characterized by mast cell infiltration of the dermis without systemic organ involvement.

Urticaria Pigmentosa (Maculopapular Cutaneous Mastocytosis)

Urticaria pigmentosa is the most frequent form of CM, also termed maculopapular cutaneous mastocytosis (MPCM). It presents as tan or reddish-brown macules and papules distributed across the trunk, extremities, and occasionally the face. These lesions represent focal dermal accumulations of mast cells. In children, lesions tend to be fewer and larger; in adults (who can develop CM as a variant of systemic disease), lesions are typically more numerous and smaller.

Darier's Sign

Darier's sign is the pathognomonic physical finding in mastocytosis. When a skin lesion is firmly stroked, the mechanical stimulation triggers mast cell degranulation, releasing histamine and other mediators locally. This produces a localized wheal-and-flare reaction (urticaria) overlying the stroked lesion within minutes. A positive Darier's sign strongly supports the diagnosis of cutaneous mastocytosis and distinguishes mast cell infiltrates from other pigmented skin lesions such as lentigines or melanocytic nevi.

Pediatric Course and Prognosis

Childhood cutaneous mastocytosis carries an excellent prognosis. The majority of children with CM — particularly those with onset in infancy — experience spontaneous regression of skin lesions by puberty as mast cell burden naturally decreases. Systemic involvement is minimal in pure CM. Known mast cell triggers in children include heat, friction and certain medications, which can provoke mediator release and symptomatic episodes, including flushing and, rarely, anaphylaxis. In a German series of 120 consecutive patients, 9% of the children had ever had anaphylaxis, and all of them had extensive skin involvement (Brockow 2008).

Other CM Subtypes

Back to Table of Contents

Systemic Mastocytosis — Subtypes and WHO Criteria

Systemic mastocytosis is defined by clonal mast cell infiltration of extracutaneous organs. The bone marrow is the primary site of involvement and the key diagnostic organ. SM is predominantly a disease of adults; the KIT D816V mutation is present in the vast majority of cases.

WHO 2022 Diagnostic Criteria

The diagnosis of SM requires fulfillment of either 1 major criterion plus 1 minor criterion, or at least 3 minor criteria. The list below follows the updated criteria of the 2021 international consensus proposal (Valent 2021):

Major criterion:

Minor criteria:

  1. 25% or more of the mast cells are spindle-shaped or have atypical morphology
  2. Detection of an activating KIT point mutation at codon 816 (typically D816V) or in other critical regions of KIT, in bone marrow or another extracutaneous organ
  3. Mast cells in bone marrow, blood, or another extracutaneous organ express one or more of CD2, CD25 and CD30, in addition to normal mast cell markers (CD117, tryptase); CD30 was added as a marker in the 2021 update
  4. Serum total tryptase persistently exceeds 20 ng/mL (does not count if there is an unrelated myeloid neoplasm; in a person with known hereditary alpha-tryptasemia the tryptase level is adjusted for the extra alpha-tryptase gene copies)

The 2021 update also defines bone marrow mastocytosis as SM without skin lesions and without B- or C-findings.

SM Subtypes (in Order of Increasing Severity)

C-Findings (Organ Damage Markers)

C-findings represent end-organ damage attributable to mast cell infiltration and define the threshold between smoldering/indolent and aggressive disease:

Back to Table of Contents

Clinical Manifestations — Mediator Symptoms

A defining feature of mastocytosis — across all subtypes — is the release of preformed and newly synthesized mast cell mediators. These episodes can occur spontaneously or be provoked by identifiable triggers. The main mediators involved include histamine, tryptase, prostaglandin D2, heparin, leukotrienes (LTC4, LTD4), and cytokines (interleukin-6 (IL-6), tumor necrosis factor-alpha).

Flushing

Episodic flushing — sudden reddening and warmth of the face, neck, and upper chest — is one of the most common presenting symptoms. Flushing in mastocytosis is driven primarily by histamine and prostaglandin D2 rather than the catecholamine-mediated flushing of pheochromocytoma. Common triggers include:

Urticaria and Pruritus

Generalized or localized itching is nearly universal in cutaneous disease and common in SM. Mechanical stimulation (Darier's sign) can provoke hive formation at lesion sites. Aquagenic urticaria (itching triggered by water contact) also occurs in some patients.

Gastrointestinal Symptoms

Gastrointestinal mast cell accumulation produces multiple effects. Histamine stimulates gastric acid hypersecretion via H2 receptors on parietal cells, leading to peptic ulcer disease, epigastric pain, and reflux. Mast cell infiltration of the intestinal wall causes cramping, bloating, diarrhea, and in severe cases malabsorption with weight loss. Abdominal pain is among the most debilitating symptoms for many patients with SM and frequently requires multi-drug management.

Neurological and Cognitive Symptoms

Headache, difficulty concentrating, and the constellation of symptoms collectively termed "brain fog" are reported frequently. These symptoms may be histamine-mediated (histamine crosses the blood-brain barrier and modulates neurological function via H1 and H3 receptors) or related to prostaglandin and cytokine release. Depression and anxiety are also increased in mastocytosis populations.

Anaphylaxis

Anaphylaxis — systemic, potentially life-threatening mast cell degranulation — is a major concern in all SM patients. Several features are distinctive:

Importantly, serum tryptase measured 1-3 hours after an anaphylactic episode is markedly elevated in virtually all SM patients (due to the large mast cell burden); a persistently elevated tryptase weeks after the acute event suggests SM as the underlying diagnosis.

Back to Table of Contents

Bone Manifestations and Osteoporosis

Skeletal disease is a major and underrecognized complication of systemic mastocytosis, even in the indolent subtype. Mast cells release multiple mediators that directly perturb bone remodeling:

Osteoporosis

Osteoporosis occurs at significantly higher rates in SM patients compared to age-matched controls. Fractures — including vertebral compression fractures — are common and can be the presenting manifestation of previously undiagnosed SM. The lumbar spine is most frequently affected. Osteoporosis in SM can be severe even in young patients and in the absence of other C-findings, which is why bone density is commonly checked in all SM patients regardless of subtype. A 2016 review describes osteoporosis as one of the most frequent manifestations of SM, particularly in adults, often complicated by repeated fragility fractures, mainly of the vertebrae (Rossini 2016).

A DEXA (dual-energy X-ray absorptiometry) scan is commonly done at the time of diagnosis in SM. Bisphosphonate therapy (alendronate orally, or zoledronate intravenously for severe cases) is used for patients with low bone mineral density (T-score below -2.5) or with prevalent fragility fractures, and DEXA is commonly repeated each year during treatment. Calcium and vitamin D supplements are commonly added.

Osteosclerosis

A paradoxical increase in bone density — osteosclerosis — occurs in a subset of SM patients, particularly affecting the axial skeleton (spine, pelvis). This results in abnormally dense, thickened trabeculae on imaging. Patients may simultaneously have osteosclerotic regions alongside osteoporotic regions, creating a mixed lytic/sclerotic pattern on radiographs or computed tomography (CT) scans. Osteosclerosis is more common in patients with higher mast cell burden and advanced SM subtypes. Despite the radiographic density, structural bone quality is abnormal and fracture risk may still be elevated.

Radiologic Assessment

Plain radiographs of the spine and pelvis can identify mixed lytic/sclerotic changes. Computed tomography provides higher resolution detail of bone architecture. A nuclear medicine bone scan (technetium-99m) can help identify sites of active bone turnover. Magnetic resonance imaging (MRI) of the spine is sensitive for detecting mast cell infiltration of vertebral marrow (hypointense on T1, variable on T2) and associated marrow edema.

Back to Table of Contents

Diagnosis — Laboratory and Pathology

Diagnosis of mastocytosis integrates clinical assessment, laboratory studies, imaging, and tissue biopsy. A systematic approach is essential given the heterogeneity of presentations.

Serum Tryptase

Serum total tryptase is the most clinically useful biomarker for mastocytosis. Tryptase is a serine protease stored in mast cell secretory granules. In healthy individuals, baseline serum tryptase is typically below 11.4 ng/mL. Key interpretive points:

KIT D816V Mutation Testing

Detection of KIT D816V is a minor diagnostic criterion and critical for treatment selection. Testing options include:

Bone Marrow Biopsy

Bone marrow trephine biopsy is required to fulfill the major diagnostic criterion for SM and to assess disease burden. A comprehensive biopsy evaluation includes:

Skin Biopsy

If urticaria pigmentosa lesions are present, punch biopsy of a representative lesion confirms dermal mast cell infiltration. Staining with tryptase or CD117 highlights the accumulated mast cells. A positive skin biopsy in the appropriate clinical context (with Darier's sign) strongly supports the diagnosis and may spare some patients the need for immediate bone marrow evaluation.

Additional Laboratory Studies

Back to Table of Contents

Treatment — Symptomatic Management

Symptom control targeting mast cell mediator effects is the foundation of treatment for all mastocytosis patients, including those with CM and indolent SM who do not require cytoreductive therapy.

Antihistamines

Antihistamines are the usual first-line treatment for patients with symptoms:

Epinephrine Auto-Injector

The 120-patient anaphylaxis study described above concluded that adults, and children with extensive skin disease, have an increased risk of severe anaphylaxis, and its authors recommend an emergency set of medication including epinephrine (Brockow 2008). In practice, people with systemic mastocytosis — and people with skin-only disease who have had anaphylaxis or significant mediator symptoms — are commonly prescribed two epinephrine auto-injectors (0.3 mg each). Two devices are prescribed because a single dose may be insufficient for severe anaphylaxis in SM patients given their high mast cell burden. Training patients, family members and caregivers to recognize anaphylaxis and use the injector is part of this practice. The reasoning given is that using epinephrine when it turns out not to be needed carries less risk than delaying it during anaphylaxis.

Cromolyn Sodium

Oral cromolyn sodium (disodium cromoglycate) is a mast cell stabilizer taken four times daily before meals and at bedtime. It is poorly absorbed from the gastrointestinal tract, meaning its primary action is local stabilization of intestinal mast cells. It is effective for abdominal cramping, diarrhea, bloating, and abdominal pain in SM. It has minimal systemic side effects given its poor absorption.

Bisphosphonates and Bone Protection

Trigger Avoidance

Known triggers that patients commonly learn to recognize and keep away from include:

Venom Immunotherapy

Venom immunotherapy (VIT) — subcutaneous desensitization with Hymenoptera venom extract — is widely used for SM patients who have experienced venom-triggered anaphylaxis or who have venom sensitization (positive skin test or specific immunoglobulin E). Key points for SM-specific VIT:

Back to Table of Contents

Treatment — Advanced Systemic Mastocytosis

Advanced SM — including aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL) — requires cytoreductive therapy to reduce mast cell burden and reverse organ damage.

Avapritinib

Avapritinib represents the most significant therapeutic advance in mastocytosis treatment. It is a highly selective type I kinase inhibitor designed specifically to inhibit the D816V mutant form of KIT. This selectivity is critical: the KIT D816V mutation is in the activation loop of the kinase and confers resistance to imatinib and other earlier-generation tyrosine kinase inhibitors that target the inactive (type II) kinase conformation.

Midostaurin

Midostaurin was the first U.S. Food and Drug Administration-approved drug for advanced SM (2017). It is a multi-kinase inhibitor targeting KIT D816V along with FLT3, PKC-alpha, PKC-beta, and VEGFR. It is less KIT D816V-selective than avapritinib. In the pivotal open-label trial (89 evaluable patients with mastocytosis-related organ damage, 100 mg twice daily), the overall response rate was 60%, and 45% had a major response — complete resolution of at least one type of mastocytosis-related organ damage. Median overall survival was 28.7 months, and 9.4 months in the 16 patients with mast cell leukemia. New or worsening severe low neutrophil counts, anemia and low platelet counts occurred in 24%, 41% and 29% of patients, mostly in those whose counts were already low (Gotlib 2016). Midostaurin 100 mg twice daily (with food) is the approved regimen. Common side effects include nausea, vomiting, and fatigue. It is also approved for FLT3-mutated acute myeloid leukemia, which is relevant for SM-AHN patients with concurrent AML.

Cladribine (2-CdA)

Cladribine, a purine nucleoside analog, was a principal cytoreductive agent for ASM before the KIT inhibitor era. It induces mast cell apoptosis through incorporation into DNA during replication and inhibition of DNA repair. Cladribine reduces mast cell burden and improves C-findings in a subset of patients but produces significant immunosuppression (particularly CD4+ T cell depletion). It remains an option in resource-limited settings or in patients not eligible for KIT inhibitors.

Interferon-Alpha

Interferon-alpha (with or without corticosteroids) was used in earlier decades as cytoreductive therapy for ASM. Response rates were moderate and treatment was associated with substantial toxicity (flu-like symptoms, depression, cytopenias). With the availability of avapritinib and midostaurin, interferon-alpha has largely been displaced from frontline advanced SM treatment but may still be used in certain situations.

Allogeneic Stem Cell Transplantation

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered for patients with MCL or refractory ASM who are medically fit for the procedure and have a suitable donor. Allo-HSCT can achieve long-term remission but carries substantial treatment-related mortality (20-30% in most series for advanced SM patients given their typically older age and organ dysfunction). The availability of effective KIT inhibitors has altered the treatment sequencing, and allo-HSCT is generally reserved for patients who fail or are intolerant to avapritinib-based therapy.

Back to Table of Contents

Hereditary Alpha-Tryptasemia

Hereditary alpha-tryptasemia (HαT) is a recently characterized germline condition that needs to be told apart from mastocytosis in patients with elevated baseline serum tryptase and systemic symptoms.

Genetics and Mechanism

HαT is caused by increased copy numbers of the TPSAB1 gene, which encodes alpha-tryptase. Normally, individuals carry two copies of TPSAB1 (one per chromosome). In HαT, one or both chromosomes carry additional TPSAB1 copies (duplex, triplex, or tetraplex), resulting in constitutively increased tryptase production even in the absence of mast cell clonal expansion. HαT follows an autosomal dominant inheritance pattern and is present in approximately 5% of the general population (4.4% of the control group in a 2021 study, Greiner 2021).

Clinical Presentation

HαT produces a multisystem symptom complex that substantially overlaps with mastocytosis and mast cell activation syndrome:

Distinguishing HαT from Mastocytosis

The distinction is critical because the prognosis and management differ substantially:

Management of HαT focuses on symptom control (antihistamines, avoiding triggers) rather than cytoreductive therapy; no mast cell cytoreduction is indicated because there is no clonal expansion.

Back to Table of Contents

Key Research Papers

  1. Valent P, Horny HP, Escribano L, et al. "Diagnostic criteria and classification of mastocytosis: a consensus proposal." Leuk Res. 2001;25(7):603-625. — PubMed PMID: 11377686
  2. Valent P, Akin C, Hartmann K, et al. "Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal." HemaSphere. 2021;5(11):e646. — PubMed PMID: 34901755
  3. Pardanani A. "Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management." Am J Hematol. 2019;94(3):363-377. — PubMed PMID: 30536695
  4. Gotlib J, Reiter A, Radia DH, et al. "Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial." Nat Med. 2021;27(12):2192-2199. — PubMed PMID: 34873345
  5. DeAngelo DJ, Radia DH, George TI, et al. "Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial." Nat Med. 2021;27(12):2183-2191. — PubMed PMID: 34873347
  6. Gotlib J, Kluin-Nelemans HC, George TI, et al. "Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis." N Engl J Med. 2016;374(26):2530-2541. — PubMed PMID: 27355533
  7. Greiner G, Sprinzl B, Górska A, et al. "Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis." Blood. 2021;137(2):238-247. — PubMed PMID: 32777817
  8. Gotlib J, Castells M, Elberink HO, et al. "Avapritinib versus Placebo in Indolent Systemic Mastocytosis." NEJM Evid. 2023;2(6):EVIDoa2200339. — PubMed PMID: 38320129
  9. Brockow K, Jofer C, Behrendt H, Ring J. "Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients." Allergy. 2008;63(2):226-232. — PubMed PMID: 18186813
  10. Rossini M, Zanotti R, Orsolini G, et al. "Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis." Osteoporos Int. 2016;27(8):2411-2421. — PubMed PMID: 26892042
  11. Carter MC, Uzzaman A, Scott LM, Metcalfe DD, Quezado Z. "Pediatric mastocytosis: routine anesthetic management for a complex disease." Anesth Analg. 2008;107(2):422-427. — PubMed PMID: 18633019
  12. Akin C. "Mast cell activation syndromes." J Allergy Clin Immunol. 2017;140(2):349-355. — PubMed PMID: 28780942

PubMed Topic Searches

  1. Systemic mastocytosis diagnosis and treatment — PubMed
  2. KIT D816V mutation mast cell — PubMed
  3. Avapritinib mastocytosis — PubMed
  4. Mastocytosis anaphylaxis venom immunotherapy — PubMed
  5. Hereditary alpha-tryptasemia TPSAB1 — PubMed

Back to Table of Contents

Connections

Back to Table of Contents